Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exosomes plus hydroquinone for resistant facial melasma
IRCT20140705018373N8Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jun 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of allogenic adipose mesenchymal stem cell-derived exosomes and hydroquinone in melasma (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Response to treatment and Treatment side effects. Started Jun 2025; status: completed.
02
Drugs
allogenic adipose mesenchymal stem cell-derived exosomeshydroquinone
03
Conditions
melasma
Beyond the preview
Go deeper on IRCT20140705018373N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140705018373N8.